-
Bal Pharma Analyst Review 2027: Revenue Up 22% and Profit Doubles, but Debt Is Heavy
- November 20, 2026
- Posted by: Chaitanya Auti
- Category: Market
No Comments
Bal Pharma, a Bengaluru-based maker of APIs and formulations, grew Q2 FY27 revenue 22% to ₹90 crore and nearly doubled profit to ₹1.43 crore. With no brokerage coverage, thin margins and debt above twice equity, we review the business, valuation and risks for 2027.